Kutshanje, iNovo Nordisk ikhuphe ngokusemthethweni ingxelo yayo yezemali ka-2022. Idatha ibonisa ukuba ukuthengiswa kweNovo Nordisk kwi-2022 kuya kufikelela kwi-176.954 yezigidigidi ze-Danish krone (i-US $ 24.994 yezigidigidi, ukuguqulwa kwezinga lotshintshiselwano kubhengezwe kwingxelo yonyaka, efanayo ngezantsi), ukuya kwi-26% ngonyaka, inzuzo yokusebenza iya kufikelela kwi-74.809 billion ye-krone yaseDenmark. (US $10.566 billion), up 28% ngonyaka, kunye net inzuzo iya kuba 55.525 billion Danish krone (US $7.843 billion), up 16% ngonyaka. Ukusebenza kuyamangalisa kakhulu.

Uvela phi umsebenzi obalaseleyo weNovo Nordisk? Impendulo yi-analogue ye-GLP-1. Kwimibhobho yemveliso yeNovo Nordisk, iimveliso zinokwahlulwa zibe ziindidi ezine: i-analogues ye-GLP-1, i-insulin kunye ne-analogues, i-coagulation factor kunye nezinye iihomoni ze-metabolic, kunye nokuthengiswa kwe-83.371 yezigidigidi ze-Danish krone (i-11.176 yeebhiliyoni zeedola, ngaphandle kweenaliti zokunciphisa umzimba), i-52.952 yezigidigidi zesiDanish. ikrone (i-7.479 yeebhiliyoni zeedola), i-11.706 yezigidigidi ze-Danish krone (i-1.653 yeebhiliyoni zeedola) kunye ne-7.138 yezigidigidi ze-Danish krone (i-1.008 yeebhiliyoni zeedola), ngokulandelanayo. Phakathi kwee-analogues ze-GLP-1, ukuthengiswa kwenaliti ye-Liraglutide ye-hypoglycemic iye yehla unyaka nonyaka, ngelixa.Semaglutideitsala amehlo kakhulu, ngentengiso iyonke ye-10.882 yeebhiliyoni zeedola ngo-2022.